Stock 301333 R&G PHARMASTUDIES CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News R&G PharmaStudies Co., Ltd.

Equities

301333

CNE100005K44

End-of-day quote Shenzhen S.E.
Other stock markets
 23:00:00 21/05/2024 BST 		5-day change 1st Jan Change
46.9 CNY +2.00% Intraday chart for R&G PharmaStudies Co., Ltd. +6.52% -27.26%
04-21 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
R&G PharmaStudies Co., Ltd.(XSEC:301333) added to S&P Global BMI Index
CI
R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Certain A Shares of R&G PharmaStudies Co., Ltd. are subject to a Lock-Up Agreement Ending on 3-AUG-2023.
CI
R&G Pharmastudies Co., Ltd. Implements Final Cash Dividend on A Shares for 2022, Payable on 29 June 2023
CI
R&G Pharmastudies Co., Ltd. Approves the Cash Dividend for the Year 2022
CI
R&G Pharmastudies Co., Ltd. Proposes Cash Final Dividend for 2022
CI
R&G PharmaStudies Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
R&G PharmaStudies Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
R&G PharmaStudies Co., Ltd. has completed an IPO in the amount of CNY 1.1832 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 301333 Stock
  4. News R&G PharmaStudies Co., Ltd.